eFFECTOR Therapeutics, Inc. Warrant
EFTRW
EFTRW was delisted on the 2nd of July, 2024.
1 hedge funds and large institutions have $0 invested in eFFECTOR Therapeutics, Inc. Warrant in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 12 closing their positions.
92% less funds holding
Funds holding: 12 → 1 (-11)
92% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 12
100% less capital invested
Capital invested by funds: $3.41K → $0 (-$3.41K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$1.63K |
| 2 |
Goldman Sachs
New York
|
-$757 |
| 3 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
-$358 |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$241 |
| 5 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$175 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Aristeia Capital
Greenwich,
Connecticut
| – | -$1.63K | -1,303,646 | Closed |
|
|
2
Goldman Sachs
New York
| – | -$757 | -630,539 | Closed |
|
|
WA
3
Whitebox Advisors
Minneapolis,
Minnesota
| – | -$358 | -298,145 | Closed |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$241 | -200,557 | Closed |
|
|
MI
5
MMCAP International
Grand Cayman,
Cayman Islands
| – | -$175 | -145,941 | Closed |
|
|
PA
6
Parallel Advisors
San Francisco,
California
| – | -$77 | -64,166 | Closed |
|
7
UBS Group
Zurich,
Switzerland
| – | -$64 | -63,645 | Closed |
|
|
ICM
8
III Capital Management
Boca Raton,
Florida
| – | -$45 | -36,579 | Closed |
|
|
TCM
9
Tenor Capital Management
New York
| – | -$40 | -33,333 | Closed |
|
|
WAM
10
Wolverine Asset Management
Chicago,
Illinois
| – | -$21 | -18,239 | Closed |
|
EFTRW Hedge Fund Activity: Q3 2024 in Review
1 of the 6,967 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Warrant (EFTRW) for Q3 2024, worth a combined $0 — down 100% from $3.41K a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of EFTRW and 1 opened new positions — a net loss of 11 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Aristeia Capital, exiting entirely with an estimated $1.63K sold.
- 1 institutional investor held eFFECTOR Therapeutics, Inc. Warrant (EFTRW) as of Q3 2024, down from 12 in Q2 2024.
- Funds reported $0 of eFFECTOR Therapeutics, Inc. Warrant stock for Q3 2024, down 100% quarter-over-quarter.
- 1 fund opened new eFFECTOR Therapeutics, Inc. Warrant positions in Q3 2024 and 12 closed out, a net change of -11 holders.
- The largest eFFECTOR Therapeutics, Inc. Warrant seller in Q3 2024 was Aristeia Capital, an estimated $1.63K sold.
Based on aggregated 13F filings for Q3 2024.